Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...

Bluebird acquired the platform when it bought Precision ... VIII replacement product called NovoEight, part of a broader haemophilia franchise that accounted for a little under 9% of the company ...

Sanofi R&D in its core haemophilia category is advancing on ... its sales decline in an increasingly competitive market. Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6 ...

The California Plasma Coalition (CalPlasma) today launched a statewide campaign to raise awareness of the vital role that plasma donations play in saving lives of Californians and patients around the ...

Sam Smith explores how more than a thousand haemophiliacs in the UK acquired HIV through their treatment - in what's come to be known as the contaminated blood scandal.